{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:15:17Z","timestamp":1792026917910,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50523-0","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:25:38Z","timestamp":1777969538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanistic multiscale modeling identifies putative natural tri-target candidates of MAO-B, LRRK2 and A\u2082A for Parkinson\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Oussama","family":"Khibech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Kadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdessamad","family":"Benabbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouhrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehdeh","family":"Jodeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Jodeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belkheir","family":"Hammouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allal","family":"Challioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"50523_CR1","doi-asserted-by":"crossref","unstructured":"Ou, Z. et al. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson \u2019 s Disease in 204 Countries \/ Territories From 1990 to 2019. 9, (2021).","DOI":"10.3389\/fpubh.2021.776847"},{"key":"50523_CR2","first-page":"1","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 1\u201321 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"50523_CR3","doi-asserted-by":"publisher","unstructured":"Li, M., Ye, X., Huang, Z., Ye, L. & Chen, C. Global burden of Parkinson \u2019 s disease from 1990 to 2021: a population- \u00ad based study. 1\u201310 (2025). https:\/\/doi.org\/10.1136\/bmjopen-2024-095610","DOI":"10.1136\/bmjopen-2024-095610"},{"key":"50523_CR4","doi-asserted-by":"crossref","unstructured":"Yang, R. et al. Global, regional and national burden of Parkinson\u2019s disease, 1990\u20132021: Update from the GBD 2021 study. J Neurol. Sci 125703 (2025).","DOI":"10.1016\/j.jns.2025.125703"},{"key":"50523_CR5","doi-asserted-by":"crossref","unstructured":"Su, D. et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. bmj 388, (2025).","DOI":"10.1136\/bmj-2024-080952"},{"key":"50523_CR6","doi-asserted-by":"crossref","unstructured":"Kim, T. Y. & Lee, B. D. Current therapeutic strategies in Parkinson\u2019s disease: Future perspectives. Mol Cells 100274 (2025).","DOI":"10.1016\/j.mocell.2025.100274"},{"key":"50523_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40120-025-00800-3","volume":"14","author":"T M\u00fcller","year":"2025","unstructured":"M\u00fcller, T. Update on the Present and Future Pharmacologic Treatment of Parkinson\u2019s Disease. Neurol. Ther. 14, 1769\u20131781 (2025).","journal-title":"Neurol. Ther."},{"key":"50523_CR8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/mds.30259","volume":"40","author":"MM Mouradian","year":"2025","unstructured":"Mouradian, M. M., Stoessl, A. J. & Lang, A. E. Disease-Modifying Trials in Treated Parkinson\u2019s Disease:Stable Treated Does Not Equate with Biological Stability. Mov. Disord. 40, 1778\u20131790 (2025).","journal-title":"Mov. Disord"},{"issue":"1","key":"50523_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","volume":"7","author":"RR Ramsay","year":"2018","unstructured":"Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E. & Bolognesi, M. L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl Med. 7 (1), 3 (2018).","journal-title":"Clin. Transl Med."},{"key":"50523_CR10","doi-asserted-by":"crossref","unstructured":"Bolognesi, M. L. Harnessing polypharmacology with medicinal chemistry. ACS medicinal chemistry letters vol. 10 273\u2013275 at (2019).","DOI":"10.1021\/acsmedchemlett.9b00039"},{"key":"50523_CR11","doi-asserted-by":"crossref","unstructured":"Katsoulaki, E. & Dimopoulos, D. & Hadjipavlou-litina, D. Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases. (2025).","DOI":"10.3390\/ph18060831"},{"key":"50523_CR12","doi-asserted-by":"publisher","unstructured":"Loza, M. I. & Carlsson, J. Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson \u2019 s Disease. (2018). https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00204","DOI":"10.1021\/acs.jmedchem.8b00204"},{"key":"50523_CR13","doi-asserted-by":"publisher","unstructured":"Kumar, P., Sekar, C., Thomas, S. M. & Veerabathiran, R. Exploration of Neuroprotective Therapy An overview of the role of monoamine oxidase-B in Parkinson \u2019 s disease: implications for neurodegeneration and therapy. 308\u2013318 (2024). https:\/\/doi.org\/10.37349\/ent.2024.00085","DOI":"10.37349\/ent.2024.00085"},{"key":"50523_CR14","doi-asserted-by":"publisher","unstructured":"Taymans, J. et al. Perspective on the current state of the LRRK2 fi eld. 1\u20139 (2023). https:\/\/doi.org\/10.1038\/s41531-023-00544-7","DOI":"10.1038\/s41531-023-00544-7"},{"key":"50523_CR15","doi-asserted-by":"crossref","unstructured":"Karami, M., Sanaye, P. M., Ghorbani, A., Amirian, R. & Goleij, P. Recent advances in targeting LRRK2 for Parkinson \u2019 s disease treatment. 0, (2025).","DOI":"10.1186\/s12967-025-06354-0"},{"key":"50523_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","volume":"28","author":"A Pinna","year":"2014","unstructured":"Pinna, A. Adenosine A2A receptor antagonists in Parkinson\u2019s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 28, 455\u2013474 (2014).","journal-title":"CNS Drugs"},{"key":"50523_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","volume":"16","author":"JF Chen","year":"2020","unstructured":"Chen, J. F. & Cunha, R. A. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease. Purinergic Signal. 16, 167\u2013174 (2020).","journal-title":"Purinergic Signal."},{"key":"50523_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541\u2013553 (2005).","journal-title":"NeuroRx"},{"key":"50523_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","volume":"1","author":"TT Wager","year":"2010","unstructured":"Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1, 435\u2013449 (2010).","journal-title":"ACS Chem. Neurosci."},{"key":"50523_CR20","doi-asserted-by":"publisher","unstructured":"Wu, D. & Chen, Q. The blood \u2013 brain barrier: Structure, regulation and drug delivery. (2023). https:\/\/doi.org\/10.1038\/s41392-023-01481-w","DOI":"10.1038\/s41392-023-01481-w"},{"key":"50523_CR21","doi-asserted-by":"publisher","unstructured":"Nahar, L., Charoensup, R., Kalieva, K. & Habibi, E. Natural products in neurodegenerative diseases: recent advances and future outlook. 1\u201314 (2025). https:\/\/doi.org\/10.3389\/fphar.2025.1529194","DOI":"10.3389\/fphar.2025.1529194"},{"key":"50523_CR22","doi-asserted-by":"crossref","unstructured":"Jingwen, L. et al. Phytomedicine Multiple pathways for natural product treatment of Parkinson \u2019 s disease: A mini review. 60, (2019).","DOI":"10.1016\/j.phymed.2019.152954"},{"key":"50523_CR23","doi-asserted-by":"crossref","unstructured":"Stefanson, A. L. & Bakovic, M. Falcarinol Is a Potent Inducer of Heme Oxygenase-1 and Was More Effective than Sulforaphane in Attenuating Intestinal Inflammation at Diet\u2010Achievable Doses. Oxid. Med. Cell. Longev. 3153527 (2018). (2018).","DOI":"10.1155\/2018\/3153527"},{"key":"50523_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/2212798411103010064","volume":"3","author":"P Christensen","year":"2011","unstructured":"Christensen, P. Aliphatic C17-polyacetylenes of the falcarinol type as potential health promoting compounds in food plants of the Apiaceae family. Recent. Pat. Food Nutr. Agric. 3, 64\u201377 (2011).","journal-title":"Recent. Pat. Food Nutr. Agric."},{"key":"50523_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2020.07.010","volume":"159","author":"HS Lim","year":"2020","unstructured":"Lim, H. S., Moon, B. C., Lee, J., Choi, G. & Park, G. The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson\u2019s disease. Free Radic Biol. Med. 159, 23\u201336 (2020).","journal-title":"Free Radic Biol. Med."},{"key":"50523_CR26","doi-asserted-by":"publisher","first-page":"e50764","DOI":"10.1371\/journal.pone.0050764","volume":"7","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. 20-Hydroxyecdysone protects against oxidative stress-induced neuronal injury by scavenging free radicals and modulating NF-\u03baB and JNK pathways. PLoS One. 7, e50764 (2012).","journal-title":"PLoS One"},{"key":"50523_CR27","doi-asserted-by":"crossref","unstructured":"Wang, Y. J. et al. Ethanol extract of centipeda minima exerts antioxidant and neuroprotective effects via activation of the Nrf2 signaling pathway. Oxid. Med. Cell. Longev. 9421037 (2019). (2019).","DOI":"10.1155\/2019\/9421037"},{"key":"50523_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chphma.2025.10.007","author":"O Khibech","year":"2025","unstructured":"Khibech, O. et al. CNS-safe flavone analogues as dual SARS-CoV-2 inhibitors: An integrated in- silico design study in-silico design study. ChemPhysMater https:\/\/doi.org\/10.1016\/j.chphma.2025.10.007 (2025).","journal-title":"ChemPhysMater"},{"key":"50523_CR29","unstructured":"Ouakil, A., Lachkar, N., Moussaid, F., Khibech, O. & Lachkar, M. Phytochemical Profile, Antioxidant and Antimicrobial Activities of Aerial Parts of Stachys germanica subsp. cordigera Briq : In Vitro Evaluation and In-Silico Molecular Docking Study. 13, 1548\u20131565 (2025)."},{"key":"50523_CR30","doi-asserted-by":"publisher","first-page":"26431","DOI":"10.1038\/s41598-024-75292-6","volume":"14","author":"D Gheidari","year":"2024","unstructured":"Gheidari, D., Mehrdad, M. & Karimelahi, Z. Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer\u2019s disease. Sci. Rep. 14, 26431 (2024).","journal-title":"Sci. Rep."},{"key":"50523_CR31","doi-asserted-by":"crossref","unstructured":"Hassan, A. H. E. et al. Synthesis and Biological Evaluation of O 6 -Aminoalkyl-Hispidol Analogs as Multifunctional Monoamine Oxidase-B Inhibitors towards Management of Neurodegenerative Diseases. (2023).","DOI":"10.3390\/antiox12051033"},{"key":"50523_CR32","doi-asserted-by":"publisher","unstructured":"Murugan, N. A., Muvva, C. & Jeyarajpandian, C. Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein \u2013 Inhibitor Complexes in Relevance to Developing Parkinson \u2019 s Therapeutics. https:\/\/doi.org\/10.3390\/ijms21207648","DOI":"10.3390\/ijms21207648"},{"key":"50523_CR33","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/mds.21440","volume":"22","author":"K Fuxe","year":"2007","unstructured":"Fuxe, K., Marcellino, D., Genedani, S. & Agnati, L. Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson\u2019s disease. Mov. Disord Off J. Mov. Disord Soc. 22, 1990\u20132017 (2007).","journal-title":"Mov. Disord Off J. Mov. Disord Soc."},{"key":"50523_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms26020850","volume":"26","author":"R Buccheri","year":"2025","unstructured":"Buccheri, R. et al. Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies. Int. J. Mol. Sci. 26, 1\u201312 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"50523_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.toxlet.2018.01.018","volume":"287","author":"S Wang","year":"2018","unstructured":"Wang, S., Wu, C., Liu, Z. & You, H. Studies on the interaction of BDE-47 and BDE-209 with acetylcholinesterase (AChE) based on the neurotoxicity through fluorescence, UV\u2013vis spectra, and molecular docking. Toxicol. Lett. 287, 42\u201348 (2018).","journal-title":"Toxicol. Lett."},{"key":"50523_CR36","doi-asserted-by":"crossref","unstructured":"Abbaoui, Z., Khibech, O., Oulous, A., Karci, H. & D\u00fcndar, M. In silico and in vitro evaluation of N -heterocyclic derivatives as antimicrobials: ADMET analysis, SAR, and molecular docking. 1\u201319 (2025).","DOI":"10.1007\/s40203-025-00445-y"},{"key":"50523_CR37","doi-asserted-by":"publisher","unstructured":"Hammouti, Y., Mesnard, F., Khibech, O., Taibi, M. & Belbachir, Y. Valorisation of Northern Moroccan Centaurium erythraea: Targeted Phytochemistry, Antioxidant, Antimicrobial Efficacy and Drug Likeness. 1\u201321 (2025). https:\/\/doi.org\/10.32604\/phyton.2025.071139","DOI":"10.32604\/phyton.2025.071139"},{"key":"50523_CR38","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41598-025-90088-y","volume":"15","author":"PG Camargo","year":"2025","unstructured":"Camargo, P. G. et al. In silico evaluation of N-aryl-1,10-phenanthroline-2-amines as potential inhibitors of T. cruzi GP63 zinc-metalloprotease by docking and molecular dynamics simulations. Sci. Rep. 15, 6036 (2025).","journal-title":"Sci. Rep."},{"key":"50523_CR39","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.1080\/07391102.2021.1918253","volume":"40","author":"B Ahmed","year":"2022","unstructured":"Ahmed, B., Khan, S., Nouroz, F., Farooq, U. & Khalid, S. Exploring multi-target inhibitors using in silico approach targeting cell cycle dysregulator\u2013CDK proteins. J. Biomol. Struct. Dyn. 40, 8825\u20138839 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"50523_CR40","doi-asserted-by":"crossref","unstructured":"Baddaoui, S. et al. HPLC-ESI-QTOF-MS \/ MS-Guided Profiling of Bioactive Compounds in Fresh and Stored Saffron Corms Reveals Potent Anticancer Activity Against Colorectal Cancer. 1\u201331 (2026).","DOI":"10.3390\/ph19010149"},{"key":"50523_CR41","first-page":"1","volume":"15","author":"A Kumar","year":"2025","unstructured":"Kumar, A. et al. Molecular dynamics simulation and docking studies reveals inhibition of NF-kB signaling as a promising therapeutic drug target for reduction in cytokines storms. Sci. Rep. 15, 1\u201313 (2025).","journal-title":"Sci. Rep."},{"key":"50523_CR42","unstructured":"Fiorucci, S. Activit\u00e9s biologiques de compos\u00e9s de la famille de flavono\u00efdes: approches par des m\u00e9thodes de chimie quantique et de dynamique mol\u00e9culaire. Univ Nice 211 (2006)."},{"key":"50523_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-63555-1","volume":"14","author":"S Aslam","year":"2024","unstructured":"Aslam, S., Aljawdah, H. M., Murshed, M. & Serrano, G. E. Pharmacophore modelling based virtual screening and molecular dynamics identified the novel inhibitors and drug targets against Waddlia chondrophila. Sci. Rep. 14, 1\u201315 (2024).","journal-title":"Sci. Rep."},{"key":"50523_CR44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c00921","author":"K Handa","year":"2024","unstructured":"Handa, K. et al. Prediction of Inhibitory Activity against the MATE1 Transporter via Combined Fingerprint- and Physics-Based Machine Learning Models. J. Chem. Inf. Model. https:\/\/doi.org\/10.1021\/acs.jcim.4c00921 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"50523_CR45","doi-asserted-by":"crossref","unstructured":"Rahimi, A. et al. ADMET-Guided Docking and GROMACS Molecular Dynamics of Ziziphus lotus Phytochemicals Uncover Mutation-Agnostic Allosteric Stabilisers of the KRAS Switch-I \/ II Groove. 1\u201320 (2025).","DOI":"10.3390\/ph18081110"},{"key":"50523_CR46","doi-asserted-by":"crossref","unstructured":"Sehrawat, R., Pasrija, R., Rathee, P., Kumari, D. & Khatkar, A. Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors. BMC Chem 18, (2024).","DOI":"10.1186\/s13065-024-01355-4"},{"key":"50523_CR47","doi-asserted-by":"publisher","unstructured":"Khibech, O., Bouammali, H. & Hammouti, Y. Elucidating the isorhamnetin-3-O-glucoside-iNOS interaction via molecular dynamics and Hirshfeld surface analyses. 1\u201321 (2025). https:\/\/doi.org\/10.1371\/journal.pone.0339357","DOI":"10.1371\/journal.pone.0339357"},{"key":"50523_CR48","doi-asserted-by":"publisher","first-page":"104035","DOI":"10.1016\/j.sjbs.2024.104035","volume":"31","author":"BS Alotaibi","year":"2024","unstructured":"Alotaibi, B. S. et al. Investigating mechanistic insights of curcumin in blocking the Interleukin-8 signaling pathway associated with Breast Cancer: An in-silico approach. Saudi J. Biol. Sci. 31, 104035 (2024).","journal-title":"Saudi J. Biol. Sci."},{"key":"50523_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bioinformatics\/btae416","volume":"40","author":"K Swanson","year":"2024","unstructured":"Swanson, K. et al. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics 40, 1\u20135 (2024).","journal-title":"Bioinformatics"},{"key":"50523_CR50","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., F Tillack, A. & Forli, S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"50523_CR51","doi-asserted-by":"publisher","unstructured":"Merimi, C., Benabbou, A., Fraj, E., Khibech, O. & Yahyaoui, M. I. ASEAN Journal of Science and Engineering Valorization of Imidazolium-Based Salts as Next- Generation Antimicrobials: Integrated Biological Evaluation, ADMET, Molecular Docking, and Dynamics Studies. 10\u201334 (2025). https:\/\/doi.org\/10.17509\/ajse.v6i1.89789","DOI":"10.17509\/ajse.v6i1.89789"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50523-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:14:14Z","timestamp":1783340054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50523-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50523"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50523-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20657"}}